Presents an Educational and Informative Audio Webinar

Analysis of Oligonucleotides as Biotherapeutics: Implications for the Drugs of Tomorrow

Original Broadcast Date:
Thursday, October 2, 2008
NOW AVAILABLE FOR:

Since the late 1980s and until just recently, antisense was the only oligonucleotide therapeutic game in town. Recently, the discovery of interfering RNAs, oligonucleotide aptamers, and entirely new classes of regulatory RNAs has led to an explosion of interest in genes as drugs.

Interest in therapeutic oligos has created demand for methods and instruments for analyzing these molecular classes. This webinar will present the latest techniques for identifying, characterizing, and quantifying important classes of oligonucleotide drugs including antisense phosphorothioates, RNAi agents, oligonucleotide aptamers, and PEGylated oligos.

Those who will benefit from attending this webinar include:

  • Biologists working with short gene sequences, particularly those of therapeutic interest, in such diverse areas as assay development and gene knockdowns
  • Oligonucleotide drug discovery and development scientists
  • Scientists and technicians in analytical service groups, quality control, and oligonucleotide production
  • Suppliers of oligonucleotides and reagents used in oligonucleotide research, development, drug discovery, and diagnostics
  • Regulatory experts, particularly individuals involved with development-stage oligonucleotides

Key learning points for this webinar:

  • The capabilities and limitations of oligonucleotide analytic platforms
  • How to transfer an analytical method from bench to development and production
  • Analyzing oligonucleotides in complex biological samples
  • Advances in HPLC and LC/MS techniques that can shorten analysis times
  • Regulatory and validation aspects of oligonucleotide analysis

This webinar will feature speakers who have demonstrated, through their research, a high level of appreciation for the unique analytic requirements of oligonucleotides, particularly therapeutic molecules. Ipsita Roymoulik, Ph.D. (Avecia Biotechnology), will describe methodology for robust method transfer into manufacturing. Yansheng Wu, Ph.D. (Archemix), will discuss analysis of oligonucleotide aptamers and PEGylated oligos, both with novel applications compared with RNAi. Martin Gilar, Ph.D. (Waters), will present methods for analyzing single– and double–stranded RNAi therapeutics.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

REGISTER TODAY at www.genengnews.com/oligos

 

 

 

 

 

PANELISTS



Ipsita Roymoulik, Ph.D.
Senior Analytical Chemist,
Quality Control
Avecia Biotechnology

 


Yansheng Wu, Ph.D.
Senior Scientist CMC Analytical,
Archemix

 

 

 


Martin Gilar, Ph.D.
Principal Investigator,
Waters

 

 

 


MODERATOR

John Sterling
Editor in Chief,
Genetic Engineering
& Biotechnology News

 

 

Produced with support from